
Gossip Jackal
<img alt="" height="1" width="1" />
Dusa skin cancer therapy won't get FDA incentives
BusinessWeek
Dusa Pharmaceuticals Inc. said Friday that regulators decided not to award incentives to its light-based Levulan therapy as a preventive treatment for a type of skin cancer. Its shares fell more than 12 percent. Dusa had asked the Food and Drug ...
DUSA to stop cancer trial as FDA denies orphan statusReuters
DUSA Denied Orphan Status for Skin Cancer DrugGossip Jackal
FDA rejects orphan status for DUSA drugMass High Tech
BioMedReports (subscription) -PR Newswire (press release)
all 34 news articles »
More...